RY 173.64 -0.3672% SHOP 148.58 -0.6486% TD 82.36 -0.9263% ENB 64.21 -0.2641% BN 83.24 -1.0579% TRI 230.54 0.013% CNQ 46.58 3.4881% CP 109.8 1.4131% CNR 148.11 0.8031% BMO 143.82 0.3489% BNS 73.94 0.5029% CSU 4345.0 -1.0785% CM 90.555 -0.1158% MFC 44.31 0.113% ATD 76.82 0.0521% NGT 60.2 -0.1327% TRP 69.31 1.0939% SU 56.975 0.9658% WCN 255.98 -0.7868% L 181.13 -0.1268%
Last update at 2025-01-17T21:26:00Z
DexCom (NASDAQ:DXCM) shareholder returns have been decent, earning 44% in 5 years
Sat 18 Jan 25, 01:00 PMWhy DexCom, Inc. (DXCM) Is Skyrocketing
Thu 16 Jan 25, 11:46 PM2 Healthcare Stocks to Buy Hand Over Fist in January
Thu 16 Jan 25, 10:22 AMDexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook
Tue 14 Jan 25, 01:11 PMAlphatec (ATEC) Moves 9.1% Higher: Will This Strength Last?
Tue 14 Jan 25, 11:11 AMHere's Why You Should Retain DexCom Stock in Your Portfolio for Now
Mon 13 Jan 25, 01:23 PMWhy Is Jim Cramer Mystified by DexCom, Inc. (DXCM)’s Earnings Miss and Competitive Challenges?
Wed 08 Jan 25, 09:35 PM3 Reasons to Buy DexCom Stock Like There's No Tomorrow
Mon 02 Dec 24, 12:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 390.80M | 173.90M | 225.00M | 104.20M | -126.50000M |
| Minority interest | - | - | - | - | - |
| Net income | 341.20M | 154.70M | 493.60M | 101.10M | -127.10000M |
| Selling general administrative | 1000.20M | 810.50M | 620.70M | 515.70M | 432.80M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1883.10M | 1680.50M | 1280.10M | 931.50M | 663.90M |
| Reconciled depreciation | 155.90M | 102.00M | 67.10M | 48.70M | 29.10M |
| Ebit | 391.20M | 175.40M | 299.50M | 142.30M | -132.90000M |
| Ebitda | 416.90M | 277.40M | 382.70M | 164.50M | -103.80000M |
| Depreciation and amortization | 25.70M | 102.00M | 83.20M | 22.20M | 29.10M |
| Non operating income net other | 18.00M | -3.20000M | 10.20M | 26.40M | - |
| Operating income | 391.20M | 175.40M | 299.50M | 142.30M | -186.30000M |
| Other operating expenses | 2518.60M | 2182.70M | 1627.20M | 1333.70M | 1217.90M |
| Interest expense | 18.60M | 102.00M | 84.70M | 60.30M | 22.70M |
| Tax provision | 49.60M | 19.20M | -268.60000M | 3.10M | 0.60M |
| Interest income | 18.00M | - | 16.10M | 26.40M | 2.40M |
| Net interest income | -18.60000M | -100.30000M | -68.60000M | -33.90000M | -20.30000M |
| Extraordinary items | - | - | - | - | 0.40M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 49.60M | 19.20M | -268.60000M | 3.10M | 0.60M |
| Total revenue | 2909.80M | 2448.50M | 1926.70M | 1476.00M | 1031.60M |
| Total operating expenses | 1491.90M | 1414.70M | 980.60M | 789.20M | 850.20M |
| Cost of revenue | 1026.70M | 768.00M | 646.60M | 544.50M | 367.70M |
| Total other income expense net | -0.40000M | -1.50000M | -74.50000M | -38.10000M | 80.10M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 341.20M | 154.70M | 493.60M | 101.10M | -127.10000M |
| Net income applicable to common shares | 341.20M | 154.70M | 493.60M | 101.10M | -127.10000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 6264.50M | 5391.70M | 4863.60M | 4290.50M | 2395.00M |
| Intangible assets | 134.50M | 173.30M | 42.00M | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 49.30M | 192.60M | 81.60M | 53.90M | 30.00M |
| Total liab | 4195.90M | 3259.90M | 2612.10M | 2464.00M | 1512.40M |
| Total stockholder equity | 2068.60M | 2131.80M | 2251.50M | 1826.50M | 882.60M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1240.10M | 134.30M | 125.20M | 432.10M | 88.50M |
| Common stock | 0.40M | 0.40M | 0.10M | 0.10M | 0.10M |
| Capital stock | 0.40M | 0.40M | 0.10M | 0.10M | 0.10M |
| Retained earnings | 1021.40M | 479.90M | -47.40000M | -202.10000M | -695.70000M |
| Other liab | - | 68.70M | 90.00M | 80.90M | 5.70M |
| Good will | 25.20M | 25.70M | 26.50M | 19.30M | 18.60M |
| Other assets | - | 369.30M | 220.80M | 237.80M | 14.20M |
| Cash | 566.30M | 642.30M | 1052.60M | 817.60M | 446.20M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1556.00M | 1839.30M | 720.80M | 614.10M | 360.20M |
| Current deferred revenue | 18.40M | 10.10M | 2.10M | 2.20M | 1.70M |
| Net debt | 2027.70M | 1443.10M | 769.20M | 1021.90M | 699.50M |
| Short term debt | 21.10M | 793.10M | 20.50M | 16.50M | 13.60M |
| Short long term debt | - | 772.60M | - | - | - |
| Short long term debt total | 2594.00M | 2085.40M | 1821.80M | 1839.50M | 1145.70M |
| Other stockholder equity | 1063.50M | 1663.10M | 2298.30M | 2025.30M | 1575.90M |
| Property plant equipment | - | 1135.60M | 889.90M | 515.30M | 321.30M |
| Total current assets | 4425.90M | 3668.80M | 3684.40M | 3424.80M | 1969.40M |
| Long term investments | 38.50M | - | - | - | - |
| Net tangible assets | - | 2131.80M | 2183.00M | 1826.50M | 864.00M |
| Short term investments | 2157.80M | 1813.90M | 1678.60M | 1890.10M | 1087.10M |
| Net receivables | 987.50M | 713.30M | 514.30M | 428.50M | 286.30M |
| Long term debt | 2434.20M | 1197.70M | 1702.70M | 1667.20M | 1059.70M |
| Inventory | 559.60M | 306.70M | 357.30M | 234.70M | 119.80M |
| Accounts payable | 276.40M | 901.80M | 573.00M | 163.30M | 256.40M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -16.70000M | -11.60000M | 0.50M | 3.20M | 2.30M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.40M | 0.10M | 0.10M | 0.10M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 479.90M | -47.40000M | -202.10000M | -695.70000M |
| Treasury stock | - | - | -206.20000M | -100.00000M | -100.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 36.50M | 47.10M | 2.00M | 21.40M | 14.20M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1838.60M | 1722.90M | 1179.20M | 865.70M | 425.60M |
| Capital lease obligations | 159.80M | 174.70M | 119.10M | 172.30M | 100.40M |
| Long term debt total | - | 1197.70M | 1702.70M | 1667.20M | 1059.70M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -1116.20000M | -138.50000M | 193.20M | -807.70000M | -835.20000M |
| Change to liabilities | - | 303.60M | 68.40M | 220.60M | 125.00M |
| Total cashflows from investing activities | - | -521.50000M | -216.10000M | -1018.00000M | -1015.20000M |
| Net borrowings | - | - | - | 1188.80M | 906.20M |
| Total cash from financing activities | -318.60000M | -552.50000M | 10.40M | 912.10M | 10.70M |
| Change to operating activities | - | -128.90000M | -11.00000M | 22.90M | 6.40M |
| Net income | 541.50M | 341.20M | 154.70M | 493.60M | 101.10M |
| Change in cash | -75.80000M | -410.30000M | 235.40M | 371.80M | -690.70000M |
| Begin period cash flow | 643.30M | 1053.60M | 818.20M | 446.40M | 1137.10M |
| End period cash flow | 567.50M | 643.30M | 1053.60M | 818.20M | 446.40M |
| Total cash from operating activities | 748.50M | 669.50M | 442.50M | 475.60M | 314.50M |
| Issuance of capital stock | 26.60M | 22.50M | 20.30M | 15.30M | 11.90M |
| Depreciation | 186.00M | 155.90M | 102.00M | 67.10M | 48.70M |
| Other cashflows from investing activities | - | -18.20000M | -20.10000M | -11.30000M | -835.20000M |
| Dividends paid | 1230.60M | - | - | - | - |
| Change to inventory | -252.60000M | 49.30M | -112.20000M | -114.50000M | -49.10000M |
| Change to account receivables | -260.10000M | -199.90000M | -75.50000M | -142.30000M | -60.00000M |
| Sale purchase of stock | -688.70000M | -557.70000M | 20.30M | 15.30M | 11.90M |
| Other cashflows from financing activities | -99.80000M | -17.30000M | -9.90000M | 1179.40M | -1.20000M |
| Change to netincome | - | 145.90M | 242.30M | -64.30000M | 109.00M |
| Capital expenditures | 236.60M | 364.80M | 389.20M | 199.00M | 180.00M |
| Change receivables | - | -199.90000M | -75.50000M | -142.30000M | -60.00000M |
| Cash flows other operating | - | -126.50000M | 62.80M | 15.40M | -9.80000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -404.50000M | 236.80M | 369.70M | -690.00000M |
| Change in working capital | 3.20M | 27.70M | -132.00000M | -20.80000M | 6.10M |
| Stock based compensation | 150.80M | 126.50M | 113.40M | 119.40M | 102.70M |
| Other non cash items | -78.00000M | 39.80M | 209.30M | 93.60M | 51.70M |
| Free cash flow | 511.90M | 304.70M | 53.30M | 276.60M | 134.50M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DXCM DexCom Inc |
-0.46 0.54% | 84.38 | 82.71 | 77.52 | 14.49 | 25.38 | 14.46 | 57.12 |
| ABT Abbott Laboratories |
-0.43 0.38% | 113.48 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
1.63 0.43% | 383.42 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
0.92 1.06% | 88.08 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
0.49 0.50% | 98.66 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
6340 Sequence Drive, San Diego, CA, United States, 92121
| Name | Title | Year Born |
|---|---|---|
| Mr. Kevin Ronald Sayer | Exec. Chairman, CEO & Pres | 1958 |
| Mr. Jereme M. Sylvain | Exec. VP, CFO & Chief Accounting Officer | 1980 |
| Mr. Jacob Steven Leach | Exec. VP & COO | 1978 |
| Mr. Paul R. Flynn | Exec. VP of Global Revenue | 1969 |
| Mr. Sean Christensen | Director of Corp. Affairs & Head of Investor Relations | NA |
| Mr. Michael Brown | Exec. VP & Chief Legal Officer | 1970 |
| Mr. Matthew Dolan | Exec. VP of Strategy, Corp. Devel. & Dexcom Labs | 1981 |
| Ms. Sadie M. Stern | Exec. VP & Chief HR Officer | 1975 |
| Mr. Andrew K. Balo | Exec. VP of Global Medical Affairs, Access & Evidence | 1948 |
| Mr. Steven R. Pacelli | Exec. VP & MD of Dexcom Ventures | 1972 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...